Loading...
Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
Recent major phase III trials led to the approval of immune checkpoint inhibitors (ipilimumab, pembrolizumab, and nivolumab) in metastatic malignant melanoma (MM). We aim to assess whether median progression-free survival, and 1 and 2-year overall survival (OS) rates are reliable surrogate endpoints...
Saved in:
| Published in: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Wolters Kluwer Health
2016
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4937921/ https://ncbi.nlm.nih.gov/pubmed/27368007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000003997 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|